- Home
- ARCT vs KROS Comparison
ARCT vs KROS Comparison
Compare ARCT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | KROS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 655.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARCT | KROS |
|---|---|---|
| Price | $6.61 | $17.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $38.67 | $22.20 |
| AVG Volume (30 Days) | ★ 673.7K | 597.1K |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $97,601,000.00 | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.38 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $5.85 | $9.12 |
| 52 Week High | $24.17 | $22.55 |
Technical Indicators
Market Signals| Indicator | ARCT | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 35.45 |
| Support Level | $6.02 | $19.76 |
| Resistance Level | $6.75 | $21.76 |
| Average True Range (ATR) | 0.31 | 0.81 |
| MACD | 0.13 | -0.54 |
| Stochastic Oscillator | 47.96 | 5.18 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.